Here are four things to know:
1. Imvexxy is intended to treat moderate-to-severe dyspareunia, or vaginal pain associated with sex. The condition is a symptom of vulvar and vaginal atrophy, which often occurs during menopause when women produce less estrogen.
2. The hormone therapy is administered as a softgel capsule inserted into the vagina and will be available in two doses.
3. Imvexxy contains a black box warning on its label, noting the risk of endometrial and breast cancers, cardiovascular disorders, and probable dementia.
4. TherapeuticsMD plans to conduct a post-approval observational study on the drug’s safety per the FDA’s request.
More articles on supply chain:
How Amazon’s latest patent would let customers interact with delivery drones
Allergan recalls 170k birth control samples with placebo pills in wrong order
Red Cross offers blood donors $5 Amazon gift card to boost summer donations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
